for viral RNA with high-sensitivity assays, as we are doing in Hubei Province, will be critical to ensure blood safety.

H.G. is employed by Shanghai Haoyuan Biotech Co., Ltd. No other authors have disclosures to declare.

About the Author
Dr. Chang works as research assistant professor in National Center for Clinical Laboratories, Beijing Hospital, focusing on the detection of transfusion-transmitted infectious pathogens. Dr. Zhao is chief of the laboratory department of Wuhan Blood Center. His primary focus is detection of transfusion-transmitted infectious pathogens.

References
1. Chinese Center for Disease Control and Prevention; The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. Vital surveillances: the epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19)—China, 2020. China CDC weekly 2020;2:113–122 [cited 2020 Mar 18]. http://www.ne.jp/asahi/kishimoto/clinic/cash/COVID-19.pdf
2. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506. https://doi.org/10.1016/S0140-6736(20)30183-5
3. Zhang W, Du RH, Li B, Zheng XS, Yang XL, Hu B, et al. Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes. Emerg Microbes Infect. 2020;9:386–9. https://doi.org/10.1080/22221751.2020.1729071
4. Chang L, Yan Y, Wang L. Coronavirus disease 2019: coronaviruses and blood safety. Transfus Med Rev. 2020 Feb 21 [Epub ahead of print]. https://doi.org/10.1016/j.tmrv.2020.02.003
5. Chinese Society of Blood Transfusion. Recommendations on blood collection and supply during the epidemic of novel coronavirus pneumonia in China, 1st edition [in Chinese]. 2020 Feb 5 [cited 2020 Mar 18] https://www.csbt.org.cn/plus/view.php?aid=16530

Most reverse transcription PCR protocols for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) include 2–3 targets for detection. We developed a triplex, real-time reverse transcription PCR for SARS-CoV-2 that maintained clinical performance compared with single-plex assays. This protocol could streamline detection and decrease reagent use during current high SARS-CoV-2 testing demands.

Detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) typically relies on molecular testing of respiratory tract specimens, although viral RNA can be detected in other specimens (1). Real-time reverse transcription PCR (rRT-PCR) protocols have been described for SARS-CoV-2, but most involve testing with multiple, single-plex reactions (2–6). Such algorithms use large volumes of reagents and limit laboratory testing capacity, both of which have become crucial during the ongoing coronavirus disease pandemic (7). Multiplex assays are commercially available (8,9) but require specific platforms and are more expensive than laboratory-developed methods.

Our objective was to develop an internally controlled, triplex assay to detect SARS-CoV-2 RNA in clinical samples. We initially evaluated 6 individual rRT-PCRs, 3 published by the US Centers for Disease Control and Prevention (2) that target the nucleoprotein (N) gene, N1, N2, and N3; and 3 published by Corman, et al. (4) that target RNA-dependent RNA polymerase (RdRp), envelope (E), and N genes. We performed assays in 20 µL reactions of the Luna Universal Probe One-Step RT-qPCR Kit (New England Biolabs, https://www.neb.com) on a Rotor-Gene Q (QIAGEN, https://www.qiagen.com) by using 5 µL of eluate and our standard cycling protocol (10). We extracted total nucleic acids from samples on an
EMAG (bioMérieux, https://www.biomerieux.com). We compared analytical sensitivity of the assays by using dilutions of 2 SARS-CoV-2 strains, BetaCoV/Germany/BavPat1/2020p.1 and USA-WA1/2020. The N2 and E-gene assays were the most sensitive singleplex reactions and we noted no substantial change in cycle threshold (Ct) when the assays were combined. We then optimized a triplex assay to include the following targets: N2, which is SARS-CoV-2 specific; E, which also detects SARS-related coronaviruses; and RNase P, which serves as a heterologous, intrinsic specimen control (Appendix Table). We considered samples positive when they produced exponential amplification curves that crossed the threshold for both N2 and E targets.

The dynamic range of both SARS-CoV-2 targets in the triplex assay extended from 8.0 to 2.0 log_{10} copies/µL of eluate. We evaluated the lower limit of detection by performing serial dilutions of viral transport media (VTM) from a confirmed case by using VTM from confirmed negative cases. We tested eluates in quadruplicate and calculated RNA concentrations from a 4-point standard curve of quantified ssDNA (Integrated DNA Technologies, https://www.idtdna.com). The lowest concentration at which all replicates were detected by both targets was 45 copies/µL. When performed in singleplex, the N2 assay detected RNA down to 5 copies/µL, but all replicates had Ct > 40, and the sensitivity of the E-gene assay did not change.

To evaluate specificity, we extracted total nucleic acids from 42 archived nasopharyngeal swab samples in VTM from patients who had laboratory-confirmed infections with the following viruses: other circulating coronaviruses in the United States (n = 20), influenza (n = 7), parainfluenza (n = 7), human rhinovirus (n = 6), respiratory syncytial virus (n = 3), human metapneumovirus (n = 3), and adenovirus (n = 2). Among the 42 swab samples, 6 had laboratory-confirmed co-infections with 2 viruses. All samples tested negative for both SARS-CoV-2 targets and positive for RNase P.

Finally, we tested nasopharyngeal or oropharyngeal swab samples from 27 patients with a suspected symptomatic SARS-CoV-2 infection (Table). Ten patients tested positive in the triplex assay. Results demonstrated 100% agreement with either the US Centers for Disease Control and Prevention or Corman et al. (2,4) protocols performed at CLIA-certified laboratories (Clinical Laboratory Improvement Amendments, Germany/BavPat1/2020p.1).

| Sample | Triplex real-time reverse transcription PCR | Singleplex reactions |
|--------|-------------------------------------------|---------------------|
|        | N2 target | E target | RNase P | N2 target | E target |
| No template control | ND | ND | ND | ND | ND |
| Positive control, RNA† | 29.9 | 32.0 | ND | 30.7 | 33.0 |
| CoV 01 | 19.0 | 23.1 | 21.0 | 19.2 | 23.1 |
| CoV 02 | ND | ND | 22.1 | ND | ND |
| CoV 03 | ND | ND | 22.0 | ND | ND |
| CoV 04 | ND | ND | 21.9 | ND | ND |
| CoV 05 | ND | ND | 22.4 | ND | ND |
| CoV 06 | ND | ND | 21.4 | ND | ND |
| CoV 07 | ND | ND | 21.6 | ND | ND |
| CoV 08 | 26.1 | 28.0 | 25.5 | 26.1 | 27.7 |
| CoV 09 | 20.1 | 22.0 | 22.5 | 20.3 | 22.2 |
| CoV 10 | ND | ND | 21.1 | ND | ND |
| CoV 11 | ND | ND | 22.0 | ND | ND |
| CoV 12 | ND | ND | 20.5 | ND | ND |
| CoV 13 | ND | ND | 20.9 | ND | ND |
| CoV 14 | ND | ND | 24.6 | ND | ND |
| CoV 15 | ND | ND | 28.7 | ND | ND |
| CoV 16 | 14.6 | 16.3 | 22.0 | 14.9 | 16.5 |
| CoV 17 | ND | ND | 27.6 | 44.8 | ND |
| CoV 18 | 33.1 | 35.7 | 22.5 | 31.0 | 32.9 |
| CoV 19 | ND | ND | 28.2 | ND | ND |
| CoV 20 | 18.6 | 21.3 | 22.5 | 18.9 | 21.5 |
| CoV 21 | 33.4 | 34.2 | 25.1 | 30.6 | 33.2 |
| CoV 22 | ND | ND | 21.1 | ND | ND |
| CoV 23 | 28.9 | 31.3 | 21.3 | 28.2 | 30.4 |
| CoV 24 | 30.0 | 33.4 | 21.6 | 29.1 | 31.6 |
| CoV 25 | 9.8 | 13.2 | 20.6 | 9.8 | 13.1 |
| CoV 26 | ND | ND | 21.5 | ND | ND |
| CoV 27 | ND | ND | 24.6 | ND | ND |

*CoV, coronavirus; E, envelope gene; N2, nucleocapsid 2 gene; ND, not detected; RNase P, ribonuclease P.
†Strain BetaCoV/Germany/BavPat1/2020p.1.

Table. Comparison of cycle threshold results for 27 clinical samples tested in triplex real-time reverse transcription PCR and singleplex PCR for severe acute respiratory syndrome coronavirus 2
https://www.cdc.gov/clia/about.html). Triplex results also agreed with testing in singleplex reactions except for 1 negative sample, number CoV 17, that gave a late positive signal in the N2 singleplex assay (Ct 44.8). However, no signal was detected in the E-gene singleplex. Therefore, had singleplex testing been performed, the final interpretation would not have differed.

We describe the development of an internally controlled triplex SARS-CoV-2 rRT-PCR that targets the N and E genes. The N2 and E-gene targets have proven to be sensitive in singleplex formats and assay performance remained robust to protocol changes we made during optimization in our laboratory. Of note, the triplex SARS-CoV-2 rRT-PCR has been validated only for the instruments and chemistries we describe here. This assay should be thoroughly validated before implementation in other laboratories.

Current molecular diagnostic workflows for SARS-CoV-2 contain 2 or 3 viral targets for confirmation (2–6). The triplex SARS-CoV-2 rRT-PCR we describe is consistent with this standard and demonstrated equivalent clinical performance to testing at CLIA-certified laboratories and to the component singleplex assays. In addition, the triplex format streamlines workflow and decreases reagent use. This triplex assay should, therefore, maintain accurate viral detection and improve laboratory capacity to meet the current high demand for testing.

Acknowledgments

We thank Mehul Suthar for providing extracted RNA from cultured SARS-CoV-2 at Emory University; Laurel R. Bristow, China Alaaeddine, and Ariel Kay for specimen collection; and Alejandra Rojas for her helpful comments throughout the course of this project.

SARS-CoV-2 RNA was provided by the European Virus Archive Global (EVA-GLOBAL) project, which has received funding from the European Union’s Horizon 2020 research and innovation program under grant no. 871029. Samples with other viral pathogens also were collected as part of the RSV in Older Adults and Pregnant women Study (ROAPS) sponsored by Pfizer (https://www.pfizer.com).

E.J.A. has received personal fees from AbbVie and Pfizer for consulting, and his institution receives funds to conduct clinical research from MedImmune, Regeneron, PaxVax, Pfizer, GSK, Merck, Novavax, Sanofi-Pasteur, and Micron. No other authors have conflicts to declare.

About the Author

Dr. Waggoner is an assistant professor in the Emory University Department of Medicine, Division of Infectious Diseases, Atlanta, Georgia, USA. His research focuses on the development and implementation of new diagnostic methods for viral infections and pathogens that cause an acute febrile illness in the tropics.

References

1. Wang W, Xu Y, Gao R, Lu R, Han K, Wu G, et al. Detection of SARS-CoV-2 in different types of clinical specimens. JAMA. 2020. https://doi.org/10.1001/jama.2020.3786
2. US Centers for Disease Control and Prevention. Real-time RT-PCR panel for detection 2019-novel coronavirus, instructions for use. 2020 Feb 4 [cited 2020 Feb 12] https://www.cdc.gov/coronavirus/2019-ncov/downloads/rt-PCR-panel-for-detection-instructions.pdf
3. Chu DKW, Pan Y, Cheng SMS, Hui KPY, Krishnan P, Liu Y, et al. Molecular diagnosis of a novel coronavirus (2019-nCoV) causing an outbreak of pneumonia. Clin Chem. 2020;66:549–55. https://doi.org/10.1093/clinchem/hvaa029
4. Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DKW, et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill. 2020;25. https://doi.org/10.2807/1560-7917.ES.2020.25.3.200045
5. Chan JF, Yip CC, To KK, Tang TH, Wong SC, Leung KH, et al. Improved molecular diagnosis of COVID-19 by the novel, highly sensitive and specific COVID-19-RdRp/Hel real-time reverse transcription-polymerase chain reaction assay validated in vitro and with clinical specimens. J Clin Microbiol. 2020 Mar 4 [Epub ahead of print]. https://doi.org/10.1128/JCM.00310-20
6. Shirato K, Nao N, Katano H, Takayama I, Saito S, Kato F, et al. Development of genetic diagnostic methods for novel coronavirus 2019 (nCoV-2019) in Japan. Jpn J Infect Dis. 2020 Feb 18 [Epub ahead of print]. https://doi.org/10.7883/jyoken.JJID.2020.061
7. Babiker A, Myers CW, Hill CE, Guarner J. SARS-CoV-2 testing. Am J Clin Pathol. 2020 Mar 30 [Epub ahead of print]. https://doi.org/10.1093/ajcp/aqaa052
8. cobas SARS-CoV-2. Instructions for use. Roche. 2020 [cited 2020 Mar 29]. https://diagnostics.roche.com/us/en/products/params/cobas-sars-cov-2-test.html
9. TaqPath COVID-19 Combo Kit. Instructions for use. ThermoFisher Scientific. 2020 [cited 2020 Mar 29]. https://www.thermofisher.com/content/dam/LifeTech/Documents/PDFs/clinical/taqpath-COVID-19-combo-kit-full-instructions-for-use.pdf
10. Rojas A, Diagne CT, Stittleburg VD, Mohamed-Hadley A, de Guillén YA, Balmaseda A, et al. Internally controlled, multiplex real-time reverse transcription PCR for dengue virus and yellow fever virus detection. Am J Trop Med Hyg. 2018;98:1833–6. https://doi.org/10.4269/ajtmh.18-0024

Address for correspondence: Jesse J. Waggoner, Emory University School of Medicine, Division of Infectious Diseases, 1760 Haygood Dr NE, Room E-132, Atlanta, GA 30303-3073, USA; email: jjwaggo@emory.edu
**Triplex Real-Time RT-PCR for Severe Acute Respiratory Syndrome Coronavirus 2**

**Appendix**

**Appendix Table.** Primer and probe sequences and final reaction concentrations used to severe acute respiratory syndrome coronavirus 2 by triplex real-time reverse transcription PCR

| Name                | Sequence (5′→3′)                  | Concentration, nM* | Location†       |
|---------------------|----------------------------------|--------------------|-----------------|
| 2019-nCoV_N2-F      | TTACAAACATTGGCCGCAA             | 500                | 29164–29183     |
| 2019-nCoV_N2-R      | GCACGACATTCCGAAGAA              | 500                | 29213–29230     |
| 2019-nCoV_N2-P‡     | ACAATTTGCCCCCAAGCCTTCA          | 250                | 29188–29210     |
| E_Sarbeco_F         | ACAGGTAGTTAATAGTTAAGCGT         | 400                | 26269–26294     |
| E_Sarbeco_R         | ATATGACAGCTACGCACACA            | 400                | 26360–26381     |
| E_Sarbeco_P1‡       | ACCTAAGCAGCCACCTAAGCGCTTCCG     | 200                | 26332–26357     |
| RNase P – F         | AGATTTGGGAGCCTGGAGCG            | 100                | —               |
| RNase P – R         | GAGCGGCTCTCCACACAG              | 100                | —               |
| RNase P – P‡         | TTCTGACCTGAGGCTCCGCCCG         | 50                 | —               |

*Concentration of each oligonucleotide in the final reaction mixture. RNaseP primer and probe concentrations were decreased to maintain consistent detection but minimize amplification in samples with high concentrations of human DNA.

†Genomic locations for viral primers and probes are provided based on the following reference sequences: Severe acute respiratory syndrome coronavirus 2 isolate 2019-nCoV/USA-IL1/2020, complete genome (Accession no. MN988713.1).

15′ fluorophore and 3′ quencher pairs were the following: 2019-nCoV_N2-P, FAM and BHQ-1; E_Sarbeco_P1, Quasar 670 and BHQ-2; RNase P – P, Cal Fluor Orange 560 and BHQ-1.